Predicta Med is an advanced healthcare technology company specializing in AI-driven decision support for the early detection and management of autoimmune diseases. Headquartered in Ramat Gan, Israel, the company was founded in 2019 with a mission to address the "diagnostic odyssey"?the long and complex journey many patients face before receiving an accurate autoimmune diagnosis. By leveraging deep learning and generative AI, Predicta Med identifies at-risk patients years before clinical symptoms become definitive, enabling earlier intervention and personalized care.
Core Mission and Technology Focus
The primary objective of Predicta Med is to shorten the diagnostic process for autoimmune conditions, which currently takes an average of four years and involves multiple specialists. The company?s platform serves as an "intelligence layer" for primary care physicians and specialists, connecting disparate medical data points that might otherwise be overlooked.
The PredictAI Engine
The foundation of the company's offerings is PredictAI, a proprietary deep learning engine that processes massive datasets to find subtle correlations indicative of underlying disease.
* Data Fusion: The engine aggregates and enriches data from multiple sources, including Electronic Medical Records (EMRs), insurance claims, physician notes, and laboratory results.
* Specialty-Specific Intelligence: Unlike general AI tools, Predicta Meds models are trained specifically on the nuances of immune-driven diseases, such as the progression of biomarkers and the interplay of multi-organ symptoms.
* Explainable AI: To ensure clinical trust, the platform provides "explainability" by surfacing the specific clinical features and data points that led to a high-risk recommendation.
Products and Services
Predicta Med offers a suite of AI tools designed to integrate seamlessly into existing clinical workflows, primarily targeted at healthcare providers and large health systems.
1. PredictaChart (AI Chart Summarization)
Managing complex autoimmune patients often involves reviewing hundreds of pages of unstructured medical history. PredictaChart uses Generative AI and Natural Language Processing (NLP) to synthesize this data.
* Narrative Summaries: Automatically generates concise summaries that highlight the most relevant clinical insights, such as previous failed treatments, key lab trends, and symptom onset.
* Reference Linking: Every summary is "anchored" with direct links to the original EMR source, allowing physicians to verify the veracity of the extracted information instantly.
* Time Efficiency: Reduces the "daunting task" of manual chart review, allowing specialists to focus more on the patient during consultations.
2. Early Detection & Workup Recommendations
The platform proactively identifies patients in a primary care setting who may have an undiagnosed autoimmune condition.
* Risk Scoring: Assigns a risk level for specific conditions such as Crohn's Disease, Rheumatoid Arthritis, Celiac Disease, and Colitis.
* Actionable Next Steps: When a suspicion arises, the system recommends specific diagnostic workups or specialist referrals based on established clinical guidelines.
* Validated Results: In clinical validation studies, the platform correctly identified 60% of Celiac patients up to four years before their clinical diagnosis was made.
3. PredictaMatch (Clinical Trial Matching)
Autoimmune patients often seek advanced therapies when standard treatments fail. PredictaMatch? automates the identification of eligible patients for clinical trials.
* Intelligent Matching: Compares a patient's complex multiomic and clinical profile against trial eligibility criteria.
* Increased Access: Empowers specialists to offer cutting-edge personalized care pathways while helping life science companies accelerate recruitment for rare disease studies.
Strategic Partnerships and Operational Reach
As of early 2026, Predicta Med has established significant operational footprints in both Israel and the United States.
Maccabi Healthcare Services: The company maintains a deep partnership with Israel's second-largest HMO, utilizing their vast database of EMR and claims data for model training and real-world implementation.
Mayo Clinic Platform: Predicta Med was an early participant in the Mayo Clinic Platform Accelerate program, which facilitated the validation of its algorithms against one of the world's most prestigious medical datasets.
U.S. Health Systems: The company collaborates with various U.S.-based providers and insurers, such as Hoag Health, to deploy its early detection tools within the American primary care ecosystem.
Leadership and Advisory
The company is led by a team of AI experts and clinicians:
* Shlomit Steinberg-Koch: Co-Founder and CEO.
* Benny Getz: Co-Founder and CTO.
* Medical Advisory Board: Includes renowned experts from Stanford Medicine, Mayo Clinic, Columbia University, and Sheba Medical Center.
Please note: This information is generated by AI. For legal use, verify with company sources.
